» Articles » PMID: 16530297

De Novo Syntheses of Marburg Virus Antigens from Adenovirus Vectors Induce Potent Humoral and Cellular Immune Responses

Overview
Journal Vaccine
Date 2006 Mar 15
PMID 16530297
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Marburg virus (MARV) is an African filovirus that causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, there are no MARV vaccines or therapies approved for human use. We hypothesized that developing a vaccine that induces a de novo synthesis of MARV antigens in vivo will lead to strong induction of both a humoral and cell-mediated immune response against MARV. Here, we develop and characterize three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV. Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines), led to efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also shown to be cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus. Additionally, three 1 x 10(8)pfu doses of vaccine vector were demonstrated to be safe in mice, as this did not lead to any detectable toxicity in liver or spleen. These promising results indicate that a cAdVax-based vaccine could be effective for induction of both humoral and cell-mediated immune responses to multiple strains of the Marburg virus.

Citing Articles

Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.

Alkan C, Jurado-Cobena E, Ikegami T NPJ Vaccines. 2023; 8(1):171.

PMID: 37925544 PMC: 10625542. DOI: 10.1038/s41541-023-00769-w.


Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.

Wu S, Zhang Z, Yu R, Zhang J, Liu Y, Song X Clin Vaccine Immunol. 2013; 21(2):156-64.

PMID: 24307239 PMC: 3910935. DOI: 10.1128/CVI.00560-13.


High-throughput virtual screening and docking studies of matrix protein vp40 of ebola virus.

Tamilvanan T, Hopper W Bioinformation. 2013; 9(6):286-92.

PMID: 23559747 PMC: 3607187. DOI: 10.6026/97320630009286.


Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Mooney A, Tompkins S Future Virol. 2013; 8(1):25-41.

PMID: 23440999 PMC: 3579652. DOI: 10.2217/fvl.12.122.


Forty-five years of Marburg virus research.

Brauburger K, Hume A, Muhlberger E, Olejnik J Viruses. 2012; 4(10):1878-927.

PMID: 23202446 PMC: 3497034. DOI: 10.3390/v4101878.